Table of Contents
Journal of Allergy
Volume 2013, Article ID 712090, 6 pages
Research Article

Apgar Score Is Related to Development of Atopic Dermatitis: Cotwin Control Study

1Department of Respiratory Medicine, Bispebjerg Hospital, 2400 Copenhagen, Denmark
2Danish Epidemiology Science Centre, Statens Serum Institut, 2300 Copenhagen, Denmark
3Institute of Regional Health Services Research & Odense Patient Data Explorative Network, University of Southern Denmark, 5000 Odense, Denmark
4The Danish Twin Registry, University of Southern Denmark, 5000 Odense, Denmark
5Danish Pediatric Asthma Center, Gentofte Hospital, 2900 Hellerup, Denmark
6Department of Dermato-Allergology, Gentofte Hospital, 2900 Hellerup, Denmark

Received 27 May 2013; Revised 20 September 2013; Accepted 21 September 2013

Academic Editor: S. L. Johnston

Copyright © 2013 Vibeke Naeser et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aim. To study the impact of birth characteristics on the risk of atopic dermatitis in a twin population. Methods. In a population-based questionnaire study of 10,809 twins, 3–9 years of age, from the Danish Twin Registry, we identified 907 twin pairs discordant for parent-reported atopic dermatitis. We cross-linked with data from the Danish National Birth Registry and performed cotwin control analysis in order to test the impact of birth characteristics on the risk of atopic dermatitis. Results. Apgar score, OR (per unit) = 1.23 (1.06–1.44), , and female sex, OR = 1.31 (1.06–1.61), , were risk factors for atopic dermatitis in cotwin control analysis, whereas birth anthropometric factors were not significantly related to disease development. Risk estimates in monozygotic and dizygotic twins were not significantly different for the identified risk factors. Conclusions. In this population-based cotwin control study, high Apgar score was a risk factor for atopic dermatitis. This novel finding must be confirmed in subsequent studies.